降鈣素和癌胚抗原聯(lián)合檢測(cè)在甲狀腺髓樣癌診治中的意義

陳明光

[摘要] 目的 分析降鈣素和癌胚抗原聯(lián)合檢測(cè)在甲狀腺髓樣癌診治中的意義。 方法 方便收取該院20例甲狀腺髓樣癌患者作為觀察組，再收取20名健康體檢者作為對(duì)照組，收取時(shí)間在2010年2月—2015年3月，實(shí)施化學(xué)發(fā)光法檢測(cè)兩種受檢者癌胚抗原、降鈣素水平。結(jié)果 患者術(shù)后6 d癌胚抗原（3.12±0.89）ng/mL、降鈣素水平（9.59±3.29）ng/mL與術(shù)前1 d相比顯著降低，而復(fù)發(fā)時(shí)癌胚抗原、降鈣素水平與術(shù)后6 d相比，顯著升高（P<0.05），觀察組患者降鈣素（120.04±23.49）pg/mL、癌胚抗原水平（15.01±4.23）ng/mL高于對(duì)照組健康體檢者（P<0.05），聯(lián)合檢查的敏感性顯著高于單一檢查（P<0.05）。結(jié)論 降鈣素和癌胚抗原聯(lián)合檢測(cè)能提高甲狀腺髓樣癌的敏感性，利于早期治療和早期檢測(cè)，同時(shí)還能判斷患者腫瘤復(fù)發(fā)和手術(shù)效果。

[關(guān)鍵詞] 降鈣素；癌胚抗原；甲狀腺髓樣癌

[中圖分類號(hào)] R736 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-0742（2017）06（b）-0007-03

[Abstract] Objective To analyze the significance of combined test of Calcitonin and carcinoembryonic antigen in diagnosis and treatment of medullary carcinoma of thyroid gland. Methods Convenient selection 20 cases of patients with medullary carcinoma of thyroid gland admitted and treated in our hospital were selected as the observation group， 20 cases of healthy physical examination persons were selected as the control group and the admission time was from February 2010 to March 2015， and the calcitonin and carcinoembryonic antigen levels of the two groups were tested by the chemiluminescence method. Results On 6 d after operation， the carcinoembryonic antigen（3.12±0.89）ng/mL and calcitonin （9.59±3.29）ng/mL were obviously decreased compared with those in 1 d before operation， and the calcitonin and carcinoembryonic antigen levels at recurrence were obviously increased compared with those in 6 d after operation（P<0.05）， and the calcitonin and carcinoembryonic antigen levels in the observation group were respectively （120.04±23.49）pg/mL and （15.01±4.23）ng/mL， which were higher than those in the control group（P<0.05）， and the sensitivity of combined examination was obviously higher that of the single examination（P<0.05）. Conclusion The calcitonin and carcinoembryonic antigen can improve the sensitivity of medullary carcinoma of thyroid gland， which is conducive to the early treatment and test， and it can also determine the tumor recurrence and operation effect.

[Key words] Calcitonin； Carcinoembryonic antigen； Medullary carcinoma of thyroid gland

甲狀腺髓樣癌為臨床上常見的內(nèi)分泌系統(tǒng)惡性腫瘤，由于該種腫瘤預(yù)后差、惡性程度高，而早發(fā)現(xiàn)、早診斷對(duì)甲狀腺髓樣癌患者十分重要。在臨床中甲狀腺髓樣癌無(wú)公認(rèn)腫瘤標(biāo)志物，而如何增加甲狀腺髓樣癌的檢出率為臨床主要研究目的[1-2]。因此，該院對(duì)降鈣素和癌胚抗原聯(lián)合檢測(cè)在甲狀腺髓樣癌診治中的意義進(jìn)行分析，方便選取2010年2月—2015年3月該院收治的20例甲狀腺髓樣癌患者進(jìn)行研究，現(xiàn)報(bào)道如下。

1 資料與方法

1.1 一般資料

方便收取該院收治的20例甲狀腺髓樣癌患者作為觀察組，再收取20名健康體檢者作為對(duì)照組。納入標(biāo)準(zhǔn)：①20例患者經(jīng)病理和手術(shù)結(jié)果證實(shí)為甲狀腺髓樣癌，②兩組受檢者均簽署知情同意書，參與該次研究。排除標(biāo)準(zhǔn)：①甲狀腺疾病、其他惡性腫瘤、慢性腎病、甲狀旁腺疾病、神經(jīng)內(nèi)分泌腫瘤患者，②在7 d內(nèi)采用口服補(bǔ)鈣和靜脈補(bǔ)鈣患者。觀察組患者；年齡在20～50歲之間，患者平均年齡為（36.01±1.16）歲，男性患者有10例、女性患者有10例。對(duì)照組；年齡在20～51歲之間，平均年齡為（37.21±1.24）歲，男性健康體檢者有9名、女性體檢者有11名。觀察組甲狀腺髓樣癌患者、對(duì)照組健康體檢者的各項(xiàng)資料差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05），可進(jìn)行對(duì)比。